How Long Do Mutation Test Results — Take in India?

Start with your oncologist's team rather than calling the laboratory yourself — they can trace the sample status faster and with more authority. Ask three specific things: whether the sample arrived at the laboratory, whether it was adequate for testing, and when the report is expected. If the answers are vague, ask your team to request a written status update from the lab. A call from the clinical team carries more weight with a laboratory than a call from the patient's family.

This means the tissue block sent to the laboratory did not have enough tumour cells in it for the test to run reliably. It does not mean your biopsy was done incorrectly — it means the area sampled contained more scar tissue or normal cells than tumour, which is common in certain cancer types. The options are: deeper sections from the same block, a fresh biopsy, or in some cases a liquid biopsy. Your oncologist will advise which route is right for your type of cancer and how it is staged.

This is a considered clinical decision, not a shortcut. Some treatment choices — particularly starting chemotherapy or certain immunotherapy regimens — do not always depend on every biomarker result before the first cycle. Your oncologist is weighing the urgency of starting against how much a specific result would change the plan. Ask them directly: what would the outstanding result change, and what would it not change? That conversation clarifies whether waiting has any practical benefit in your situation.

Sending tissue internationally adds transit time and customs processing on top of the laboratory's own turnaround — it is rarely faster than a well-run Indian reference laboratory. Comprehensive NGS panels from NABL-accredited Indian laboratories now analyse the same genes as international platforms and issue reports in the same format. Where international testing genuinely adds value is for rare tumour types, research-level panels not routinely available in India, or a formal second opinion on a complex result. The cost is substantially higher. Ask your oncologist what specific additional information they expect the overseas test to provide.

This is more common than most families expect. The original biopsy tissue may have been fully used in establishing the diagnosis, may have been preserved in a way that damages DNA, or may have been from a procedure done several years ago that has degraded. A repeat biopsy for molecular testing does not mean anything has changed in your cancer or that the first biopsy was wrong — it means the laboratory needs fresh, well-preserved material to run the test reliably. A liquid biopsy is sometimes offered as an alternative when a repeat biopsy is not safe.

NGS reports describe hundreds of variants. Some are well studied and have a clear treatment implication. Many are variants of uncertain significance — detected but not yet understood well enough to act on. Asking a molecular tumour board or a genomic pathologist to review the report is standard practice at thorough oncology centres, and the review typically takes one to two weeks. What it changes is not your diagnosis but the confidence with which the right targeted treatment can be matched to your tumour's specific biology.